May 8, 2019 / 2:18 PM / 3 months ago

BRIEF-Novartis' Sandoz unit defeats Amgen patent appeal related to white blood cell deficiency biosimilars

May 8 (Reuters) - u.s. Appeals court rejects amgen appeal in patent litigation related to two novartis biosimilars -- court ruling u.s. Federal circuit court of appeals upholds lower court ruling that novartis' sandoz unit did not infringe amgen patent for filgrastim and proposed pegfilgrastim biosimilars Amgen had developed filgrastim, marketed as neupogen, and pegfilgrastim, marketed as neulasta, to treat a white blood cell deficiency known as neutropenia

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below